Localized scleroderma

Current Opinion in Rheumatology

Volumn 18, Issue 6, 2006, Pages 606-613

  Laxer, Ronald M ^a,b   Zulian, Francesco ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Autoantibodies; Classification; Localized scleroderma; Morphoea; Organ involvement

Indexed keywords

AUTOANTIBODY; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN; GAMMA INTERFERON; HYDROXYCHLOROQUINE; IMIQUIMOD; IMMUNOMODULATING AGENT; METHOTREXATE; METHYLPREDNISOLONE; PENICILLAMINE; PREDNISONE; PSORALEN; SALAZOSULFAPYRIDINE; TACROLIMUS;

CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE CLASSIFICATION; HUMAN; LOCALIZED SCLERODERMA; LONG TERM CARE; MORPHEA; PATIENT MONITORING; PHOTOTHERAPY; PRIORITY JOURNAL; PUVA; REVIEW; SKIN IRRITATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MULTICENTER STUDIES; MULTICENTER STUDIES AS TOPIC; SCLERODERMA, LOCALIZED;

EID: 33750215288     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000245727.40630.c3     Document Type: Review

References (54)

1. Peterson LS, Nelson AM, Su WPD. Subspecialty clinics: rheumatology and dermatology classification of morphea (localized scleroderma). Mayo Clin Proc 1995; 70:1068-1076.
2. Zulian F, Athreya BH, Laxer RM, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children: an international study. Rheumatology (Oxford) 2006; 45:614-620. A large multicentre study reporting the epidemiological, clinical and immunological features of 750 children with localized scleroderma.
3. Zulian F, Martini G. Preliminary classification criteria for juvenile systemic sclerosis. In: Zulian F and Ruperto N, editors. Proceedings of the II Workshop on nomenclature and diagnostic criteria for Juvenile Scleroderma Syndromes; 3-6 June 2004; Padua. Padua: Associazione Il Volo; 2005. pp. 5-16.
4. Appelhans C, Breuckmann F, Gambichler T, et al. Unilateral generalized morphea is a rare variant of localized scleroderma. Eur J Med Res 2006; 11:152-156. Report of four patients with an extreme variant of a linear form of generalized morphoea.
5. Jablonska S, Blaszczyk M. Long-lasting follow-up favours a close relationship between progressive facial hemiatrophy and scleroderma en coup de sabre. J Eur Acad Dermatol Venereol 2005; 19:403-404.
6. Menni S, Marzano AV, Passoni E. Neurologic abnormalities in two patients with facial hemiathrophy and sclerosis coexisting with morphea. Pediatr Dermatol 1997; 14:113-116.
7. Blaszczyk M, Jablonska S. Linear scleroderma en coup de sabre: relationship with progressive facial hemiatrophy. Adv Exp Med Biol 1999; 455:101-104.
8. Sommer A, Gambichler T, Bacharach-Buhles M, et al. Clinical and serological characteristics of progressive facial hemiatrophy: a case series of 12 patients. J Am Acad Dermatol 2006; 54:227-233. A retrospective study on the clinical, serological, and radiographic findings of 12 patients with progressive facial hemiatrophy, underlying the pathogenetic importance of neurological involvement in the pathogenesis of progressive facial hemiatrophy.
9. Wollina U, Buslau M, Weyers W. Squamous cell carcinoma in pansclerotic morphea of childhood. Pediatr Dermatol 2002; 19:151-154.
10. Parodi PG, Roberti G, Draganic Stinco D, et al. Squamous cell carcinoma arising in a patient with long-standing pansclerotic morphea. Br J Dermatol 2001; 144:417-419.
11. Maragh SH, Davis MDP, Bruce AJ, Nelson AM. Disabling pansclerotic morphea: clinical presentation in two adults. J Am Acad Dermatol 2005; 53:S115-S119.
12. Dehen L, Roujeau JC, Cosnes A, Revuz J. Internal involvement in localized scleroderma. Medicine (Baltimore) 1994; 73:241-245.
13. Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005; 52:2873-2881. Multicentre study reporting that a quarter of 750 children with localized scleroderma present with various kinds of extracutaneous manifestations, often unrelated to the site of the skin lesions and sometimes with multiple organ involvement. The risk for developing systemic sclerosis, however, was shown to be very low.
14. Blaszczyk M, Krolicki L, Krasu M, et al. Progressive facial hemiatrophy: central nervous system involvement and relationship with scleroderma en coup de sabre. J Rheumatol 2003; 30:1997-2004.
15. Sathornsumetee S, Schanberg L, Rabinovich E, et al. Parry-Romberg syndrome with fatal brain stem involvement. J Pediatr 2005; 146:429-431. A suggestive case report describing a 2-year-old boy with relentless Parry Romberg syndrome progression with brain stem involvement leading to death.
16. DeFelipe J, Segura T, Arellano JI, et al. Neuropathological findings in a patient with epilepsy and the Parry-Romberg syndrome. Epilepsia 2001; 42:1198-1203.
17. Flores-Alvarado DE, Esquivel-Valerio JA, Garza-Elizondo M, Espinoza LR. Linear scleroderma en coup de sabre and brain calcification: is there a pathogenic relationship? J Rheumatol 2003; 30:193-195.
18. Holland KE, Steffes B, Nocton JJ, et al. Linear scleroderma en coup de sabre with associated neurologic abnormalities. Pediatrics 2006; 117:132-136.
19. Weber P, Ganser G, Frosch M, et al. Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease. J Rheumatol 2000; 27:2692-2695.
20. Peterson LS, Nelson AM, Su WP, et al. The epidemiology of morphea (localized scleroderma) in Olmsted County. J Rheumatol 1997; 24:73-80.
21. Uziel Y, Krafchik BR, Silverman ED, et al. Localized scleroderma in childhood: a report of 30 cases. Semin Arthritis Rheum 1994; 23:328-340.
22. Vancheeswaran R, Black CM, David J, et al. Childhood onset scleroderma: is it different from adult onset disease. Arthritis Rheum 1996; 39:1041-1049.
23. Marzano AV, Menni S, Parodi A, et al. Localized scleroderma in adults and children: clinical and laboratory investigations on 239 cases. Eur J Dermatol 2003; 13:171-176.
24. Zulian F, Vallongo C, de Oliveira SK, et al. Congenital localized scleroderma. J Pediatr 2006; 149:248-251. This study describes the clinical features of six neonates with localized scleroderma present at birth. The linear subtype, in four involving the face, was the exclusive manifestation of the disease.
25. Aberer E, Neumann R, Stanek G. Is localised scleroderma a Borrelia infection? Lancet 1985; 2:278.
26. Fan W, Leonardi CL, Penneys NS. Absence of Borrelia burgdorferi in patients with localized scleroderma (morphea). J Am Acad Dermatol 1995; 33:682-684.
27. Reddy SM, Pui JC, Gold LI, Mitnick HJ. Postirradiation morphea and subcutaneous polyarteritis nodosa: case report and literature review. Semin Arthritis Rheum 2005; 34:728-734. Review article reporting 25 patients with postirradiation morphoea and eight cases of panniculitis. The authors underline that radiation may be responsible for inducing some of the pathogenic changes seen in scleroderma and other autoimmune diseases.
28. Ludwig RJ, Werner RJ, Winker W, et al. Chronic venous insufficiency: a potential trigger for localized scleroderma. J Eur Acad Dermatol Venereol 2006; 20:96-99.
29. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in 'healthy' individuals. Arthritis Rheum 1997; 40:1601-1611.
30. Newkirk MM. Rheumatoid factors: what do they tell us? J Rheumatol 2002; 29:2034.
31. Vila P, Hernandez MC, Lopez-Fernandez MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72:209-213.
32. Blaszczyk M, Jarzabek-Chorleska M, Jablonska S. Relationship between cutaneous and systemic scleroderma: are immunopathological studies helpful in evaluating transition of cutaneous to systemic scleroderma? Przeglad Dermatologiczny 2000; 2:119-125.
33. Takehara K, Sato S. Localized scleroderma is an autoimmune disease. Rheumatology (Oxford) 2005; 44:274-279. A comprehensive review on the prevalence and significance of various kind of autoantibodies, cytokines and soluble receptors in localized scleroderma.
34. Ruffatti A, Peserico A, Glorioso S, et al. Anticentromere antibody in localized scleroderma. J Am Acad Dermatol 1986; 15:637-642.
35. Mimura Y, Ihn H, Jinnin M, et al. Rheumatoid factor isotypes in localized scleroderma. Clin Exp Dermatol 2005; 30:405-408.
36. el Azhary RA, Aponte CC, Nelson AM. Do antihistone autoantibodies reflect disease activity in linear scleroderma? Arch Dermatol 2004; 140:759-760.
37. Hayakawa I, Hasegawa M, Takehara K, Sato S. Anti-DNA topoisomerase IIα autoantibodies in localised scleroderma. Arthritis Rheum 2004; 50:227-232.
38. Grigolo B, Mazzetti I, Borzi RM, et al. Mapping of topoisomerase IIα epitopes recognized by autoantibodies in idiopathic pulmonary fibrosis. Clin Exp Immunol 1998; 114:339-346.
39. Sato S, Fujimoto M, Hasegawa M, Takehara K. Antiphospholipid antibody in localised scleroderma. Ann Rheum Dis 2003; 62:771-774.
40. Vila P, Hernandez MC, Lopez-Fernandez MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72:209-213.
41. Hasegawa M, FuJimoto M, Hayakawa I, et al. Antiphosphatidylserine- prothrombin complex antibodies in patients with localized scleroderma. Clin Exp Rheumatol 2006; 24:19-24.
42. Hasegawa M, Sato S, Nagaoka T, et al. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology 2003; 207:141-147.
43. Martini G, Murray KJ, Howell KJ, Zulian F. Juvenile-onset localized scleroderma activity detection by infrared thermography. Rheumatology (Oxford) 2002; 41:1178-1182.
44. Zulian F, Meneghesso D, Grisan E, et al. Computerized skin score: a new technique for the assessment of localized scleroderma [abstract]. Proceedings of the Annual European Congress of Rheumatology EULAR 2006; 21-24 June 2006; Amsterdam, The Netherlands. Ann Rheum Dis 2006; 65 (Suppl II):578. A new computerized technique for the assessment of the skin lesion in localized scleroderma. A good inter-intra-observer reliability of this technique offers a wider application in the clinical practice.
45. Liu P, Uziel Y, Chuang S, et al. Localized scleroderma: imaging features. Pediatr Radiol 1994; 24:207-209.
46. Cosnes A, Anglade MC, Revux J, Radier C. Thirteen-megahertz ultrasound probe: its role in diagnosing localized scleroderma. Br J Dermatol 2003; 148:724-729.
47. Dytoc M, Ting PT, Man J, et al. First case series on the use of imiquimod for morphoea. Br J Dermatol 2005; 153:815-820. This uncontrolled study with a new immunomodulator provides important pilot data for a more comprehensive study.
48. Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol 2005; 141:847-852. This study, in both children and adults, confirms previous findings and uses some important outcome measures.
49. Uziel Y, Feldman BM, Krafchik BR, et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000; 136:91-95.
50. Fitch PG, Retting P, Burnham JM, et al. Treatment of pediatric localized scleroderma with methotrexate. J Rheumatol 2006; 33:609-614.
51. El-Mofty M, Mostafa W, Esmat S, et al. Suggested mechanisms of action of UVA phototherapy in morphea: a molecular study. Photodermatol Photoimmunol Photomed 2004; 20:93-100.
52. Kreuter A, Hyun J, Stucker M, et al. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006; 54:440-447. This study reports that the more readily accessible UVB phototherapy is almost as effective as UVA1 in treating morphea.
53. Rose RF, Goodfield MJ. Combining PUVA therapy with systemic immunosuppression to treat progressive diffuse morphoea. Clin Exp Dermatol 2005; 30:226-228.
54. Mancuso G, Berdondini RM. Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol 2005; 152:180-182.